URAT1 inhibitor 7 NEW
Price | $195 | $483 | $692 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-12 |
Product Details
Product Name: URAT1 inhibitor 7 | CAS No.: 1632002-28-8 |
Purity: 97.65% | Supply Ability: 10g |
Release date: 2024/11/12 |
Product Introduction
Bioactivity
名稱 | URAT1 inhibitor 7 |
描述 | URAT1 inhibitor 7 is a novel and potent inhibitor of the human uric acid transporter protein URAT1 (IC50:12 nM).URAT1 inhibitor 7 inhibits CYP2C9 with an IC50 of 4.2 μM.URAT1 inhibitor 7 can be used to study hyperuricemia and gout. |
存儲條件 | store at low temperature | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (116.6 mM) |
關(guān)鍵字 | URAT1inhibitor7 |
相關(guān)產(chǎn)品 | Fraxin | Indican | Verinurad | Puliginurad | Lesinurad | Epaminurad HCl | Benzarone | Lingdolinurad | URAT1 inhibitor 1 | Dotinurad |
相關(guān)庫 | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 抑制劑庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-22 | |
$3150.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$0.00/5Kg |
VIP1Y
|
SHANGHAI GEM CHEMICAL INDUSTRY CO.,LTD.
|
2024-06-05 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY